Last reviewed · How we verify
Immedate Release Torsemide Tablets
Torsemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes.
Torsemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes. Used for Edema associated with congestive heart failure, Edema associated with renal disease, Hypertension.
At a glance
| Generic name | Immedate Release Torsemide Tablets |
|---|---|
| Also known as | IR Torsemide Tablets |
| Sponsor | Sarfez Pharmaceuticals, Inc. |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Torsemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This leads to increased urine output and reduced blood volume and pressure. The immediate-release formulation provides rapid onset of diuretic action, typically within 1 hour of oral administration.
Approved indications
- Edema associated with congestive heart failure
- Edema associated with renal disease
- Hypertension
Common side effects
- Hypokalemia
- Hyperuricemia
- Ototoxicity (at high doses)
- Dehydration
- Hypotension
- Hyperglycemia
Key clinical trials
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immedate Release Torsemide Tablets CI brief — competitive landscape report
- Immedate Release Torsemide Tablets updates RSS · CI watch RSS
- Sarfez Pharmaceuticals, Inc. portfolio CI